The present disclosure relates to a method of an anti-PD-1 antibody in combination with chemotherapy in treating esophageal cancer. In particular, the present disclosure relates to a method of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a chemotherapeutic agent in the preparation of a medicament for treating esophageal cancer. The present disclosure also relates to related drug combination and kit. The present disclosure also relates to a method of a reagent for detecting a gene amplification of chromosome 11q13 region in a test kit for predicting the therapeutic effect of the anti-PD-1 antibody and/or the antigen-binding fragment thereof on an esophageal cancer patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
The present application provides a bispecific antibody targeting PD-1 and VEGF, and a composition comprising same. Also provided are a nucleic acid molecule encoding the bispecific antibody of the present application, a vector and a host cell for expressing the bispecific antibody of the present application, and therapeutic and diagnostic methods using the antibody or antigen-binding fragment thereof of the present application and the use thereof.
The present disclosure provides a stable anti-PD-1 antibody pharmaceutical composition and use thereof. The pharmaceutical composition includes a buffer and an anti-PD-1 antibody or an antigen-binding fragment thereof; and the anti-PD-1 antibody or the antigen-binding fragment thereof has a concentration of about 100-250 mg/mL, and includes an LCDR1, an LCDR2 and an LCDR3 having amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and an HCDR1, an HCDR2 and an HCDR3 having amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and and the pharmaceutical composition has a pH of about 5.0-6.5. The present disclosure also provides an injection including the pharmaceutical composition and use of the pharmaceutical composition and the injection in preparing a medicament for treating a disease or disorder by eliminating, inhibiting or reducing PD-1 activity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
4.
COMPOSITIONS AND METHODS FOR TREATING SOLID TUMORS WITH ANTI-BTLA AS COMBINATION THERAPY
Relates to the use of an anti-BTLA antagonist (including antibodies and antigen-binding fragments) in combination therapy with other immune checkpoint inhibitor therapy such as anti-PD-1 or anti-PD-L1, and methods of selecting subjects in need of treatment. Preferably, lung cancer is selected from NSCLC and SCLC.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
An antibody specifically binding to CD112R or an antigen binding fragment thereof, a composition comprising same, a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen binding fragment thereof, a treatment and diagnostic method using the antibody or the antigen binding fragment thereof, and use of the antibody or the antigen binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention discloses a method of treating a patient suffering from locally advanced or metastatic urothelial carcinoma, comprising determining a tumor mutational burden of the patient; identifying a candidate exhibiting a high tumor mutational burden, wherein the high tumor mutational burden is ≥10 mutations/Mbp; and administering to the candidate a therapeutically effective amount of toripalimab. The present invention also discloses a method of identifying a candidate having mutations in one or more of the following genes occurred in tumor cells: SMARCA4 and RB1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to a method of an anti-PD-1 antibody in combination with first-line chemotherapy in the treatment of advanced non-small cell lung cancer. Specifically, the present disclosure relates to use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a first-line chemotherapeutic agent in the preparation of a drug for treating non-small cell lung cancer (NSCLC). The present disclosure also relates to a related drug combination and a kit.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
C07B 59/00 - Introduction of isotopes of elements into organic compounds
9.
BISPECIFIC ANTIBODY TARGETING CD112R AND TIGIT AND USE THEREOF
The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are anti-LAIR1 antibodies and uses thereof in the treatment of cancer, inflammation and autoimmune diseases. LAIR1 targeting leukemia blast cells would represent a safer and more effective treatment modality for AML patients. Furthermore, using hybridoma screening technique, anti-human LAIR1 specific monoclonal antibodies are successfully generated, where the antibodies inhibited the binding of LAIR1 to collagen I, and showed strong internalization in a dose-dependent manner, indicating the potentials in the development of antibody-drug conjugate.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention relates to a linker for an antibody-drug conjugate and a use thereof. Specifically, a linker represented by formula I is provided. An antibody-drug conjugate prepared by means of the linker are more stable and more effective, and can be effectively used for treating various diseases such as tumors. Further provided are an antibody-drug conjugate prepared using the linker and a use of the antibody-drug conjugate in treating tumors or other diseases.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/51 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C07D 309/02 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 307/02 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
C07D 247/00 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups
12.
ANTI-TIGIT ANTIBODY PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Provided are a CLDN-18.2 specific binding antibody or an antigen binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule coding the antibody or the antigen binding fragment thereof, an expression vector and a host cell for expressing the antibody or the antigen binding fragment thereof, and a therapeutic or diagnostic method and use for the antibody or the antigen binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an antibody specifically binding to CGRP or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and therapeutic and diagnostic methods and use of the antibody or the antigen-binding fragment thereof.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are a stable anti-CD112R antibody pharmaceutical composition and use thereof. The pharmaceutical composition contains a buffer solution and an anti-CD112R antibody or an antigen-binding fragment thereof. The concentration of the anti-CD112R antibody or the antigen-binding fragment thereof is about 1-100 mg/mL. All components of a developed antibody preparation interact and cooperate with each other to provide a storage environment suitable for the long-term preservation of an anti-CD112R monoclonal antibody. The antibody preparation has high stability, and a strong tolerance to high temperatures, shaking, and repeated freezing and thawing. Additionally, the antibody preparation can block the interaction of CD112/CD112R, improve the activation capacity of T cells, mobilize an immune system, and exert a stronger tumor-killing effect.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
16.
STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Biomarkers and methods for the treatment of non-small cell lung cancer (NSCLC). Biomarkers for patient selection and prognosis, and diagnostic kit for analyzing the biomarkers.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Use of a CD73 antibody or an antigen binding fragment thereof in preparing a medicament for treating solid tumor in a subject in need thereof, wherein the medicament further comprising a PD-1 antagonist.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to the use of an anti-PD-1 antibody or an antigen-binding fragment thereof in preparing a drug for preventing or treating a malignant cancer, and the use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and gemcitabine-cisplatin in preparing a drug for preventing or treating a malignant cancer. The malignant cancer is preferably nasopharyngeal carcinoma. The present invention also relates to a method for using a biomarker to predict the therapeutic effect of the anti-PD-1 antibody or the antigen-binding fragment thereof in treatment of nasopharyngeal carcinoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a combination of an anti-PD-1 antibody and an anti-EGFR antibody and the use thereof in the treatment of head and neck squamous cell carcinoma. Specifically, provided is a drug combination comprising an anti-PD-1 antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof. The drug combination exhibits good curative effect in the treatment of head and neck squamous cell carcinoma.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to the use of an anti-BTLA antagonist (including antibodies and antigen binding fragments) in the treatment of various tumors, either as a mono therapy or a. combination therapy with other immune checkpoint inhibitor therapy such as anti-PD-1 or anti- PD-L1, and methods of selecting subjects in need of treatment. Preferably, various solid tumors are treated.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to the use of an anti-BTLA antagonist (including antibodies and antigen binding fragments) in the treatment of various tumors, either as a mono therapy or a combination therapy with other immune checkpoint inhibitor therapy such as anti-PD-1 or anti-PD-L1, and methods of selecting subjects in need of treatment. Preferably, various solid tumors are treated.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a combination of an anti-PD-1 antibody or an antigen binding fragment of the anti-PD-1 antibody and a cytotoxic anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer. Specifically, Provided are a combination of an anti-PD-1 antibody or an antigen-binding fragment of the anti-PD-1 antibody, an anti-folate metabolism anticancer drug, and a platinum anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer that has failed EGFR-TKI treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
An antibody specifically binding to CTLA-4 or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or an antigen-binding fragment thereof, and therapcutic and diagnostic methods and the use of the antibody or an antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention belongs to the field of biological medicines, and relates to an anti-DKK1 antibody, a pharmaceutical composition thereof and the use thereof. Specifically, the present invention relates to an anti-DKK1 antibody or an antigen-binding fragment thereof. The anti-DKK1 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein the amino acid sequence of HCDR1 is selected from SEQ ID NO: 1, etc.; the amino acid sequence of HCDR2 is selected from SEQ ID NO: 2, etc.; the amino acid sequence of HCDR3 is selected from SEQ ID NO: 3, etc.; the amino acid sequence of LCDR1 is selected from SEQ ID NO: 4, etc.; the amino acid sequence of LCDR2 is selected from SEQ ID NO: 5, etc.; and the amino acid sequence of LCDR3 is selected from SEQ ID NO: 6, etc. The anti-DKK1 antibody of the present invention can specifically bind to DKK1 to effectively block the Wnt signal pathway, thereby inhibiting the promotion effect of DKK1 on a tumor microenvironment and the promotion effect on tumor development. The anti-DKK1 antibody has a good anti-tumor effect.
The present invention provides a bispecific antibody targeting CD3 and CD20 and a composition comprising same. Further provided are a nucleic acid molecule encoding the bispecific antibody of the present invention, a vector and a host cell for expressing the bispecific antibody of the present invention, and a therapeutic and diagnostic method and a use of the antibody of the present invention or an antigen-binding fragment thereof.
The present invention provides a pharmaceutical combination of an anti-PD-1 antibody or an antigen binding fragment thereof and an anti-VEGF antibody or an antigen binding fragment thereof, and a use of a pharmaceutical combination in preparation of a drug for treating hepatocellular carcinoma. The anti-PD-1 antibody or the antigen binding fragment thereof comprises amino acid sequences LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and amino acid sequences HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.
Provided in the present invention are a pharmaceutical composition of an anti-CTLA-4 antibody, an injection agent, and the use thereof. The pharmaceutical composition or injection agent contains a buffer solution and an anti-CTLA-4 antibody or an antigen binding fragment thereof, wherein the concentration of the anti-CTLA-4 antibody or the antigen binding fragment thereof is approximately 1-100 mg/mL. According to the present invention, by means of selecting an appropriate buffer system and pH and optimizing a stabilizer and a surfactant, the developed antibody preparation can be used for intravenous injection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a neuroendocrine neoplasm. The present disclosure also relates to an agent or a kit for detecting an ARID1A gene mutation or amplification, or a chromosomal gene rearrangement, and use of the detection agent or kit in predicting the therapeutic effect of an anti-PD-1 antibody or an antigen-binding fragment thereof in the treatment of a patient with a neuroendocrine neoplasm.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided are a stable pharmaceutical composition of an anti-IL-17A antibody and an application thereof in medicine. The pharmaceutical composition contains an anti-IL-17A antibody or an antigen-binding fragment thereof, and a buffer, can further contain at least one stabilizer, and can further contain a surfactant.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided are an antibody capable of specifically binding to BCMA or an antigen-binding fragment of the antibody, and a pharmaceutical composition comprising same. Also provided are a polynucleotide molecule encoding the antibody or the antigen-binding fragment thereof, an expression vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and a use of the antibody or the antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a stable pharmaceutical composition comprising an anti-BTLA (B and T lymphocyte attenuator) antibody and use thereof in medicines. The pharmaceutical composition comprises an anti-BTLA antibody and a buffer, further comprises at least one stabilizer, and optionally further comprises a surfactant.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Provided are an antibody capable of specifically binding to 4-1 BB or an antigen binding fragment thereof, and a pharmaceutical composition comprising same. Also provided are a polynucleotide molecule encoding the antibody or the antigen binding fragment thereof, an expression vector for expressing the antibody or the antigen binding fragment thereof, a host cell, and a use of the antibody or the antigen binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a malignancy. In particular, the present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a sarcoma, alveolar soft part sarcoma, angiosarcoma and undifferentiated polymorphic sarcoma, and use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of lymphoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an antibody binding to CD3 and a use thereof, and a bispecific antibody capable of binding to CD3 and a tumor-associated antigen at the same time. The bispecific antibody comprises a first binding domain, a second binding domain, and a third binding domain, wherein the first binding domain binds to CD3, and the second binding domain and the third binding domain bind to a tumor-associated antigen. The first binding domain has the form of a Fab molecule, the second binding domain has the form of a Fv molecule or a scFv molecule, and the third binding domain has the form of a Fab molecule. The present bispecific antibody may bind and activate CD3-positive T cells while binding to a tumor-associated antigen-expressing cell, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. Meanwhile, also provided are a pharmaceutical composition containing the bispecific antibody and methods for preparing and using the bispecific antibody.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure relates to use of an anti-PD-1 antibody in the treatment of melanoma. The present disclosure also relates to use of an agent for detecting BRAF, NRAS, and CDK4/CCND1 gene mutations in a detection kit for predicting the therapeutic effect of an anti-PD-1 antibody and/or an antigen-binding fragment thereof administered alone to a patient with melanoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 35/04 - Antineoplastic agents specific for metastasis
38.
IMPROVED URICASE AND METHOD FOR TREATING HYPERURICEMIA USING SAME
Provided are an improved uricase, a method for treating hyperuricemia using the same, and a corresponding pharmaceutical composition. The improved uricase comprises an amino acid sequence having at least about 90% identity with SEQ ID NO: 1, wherein the sequence is not SEQ ID NO: 1.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
39.
ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Provided are an anti-CLDN-18.2 antibody-drug conjugate that specifically binds to CLDN-18.2 and a composition comprising same. Also provided are a method for using the antibody-drug conjugate of the present invention and a use thereof.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A stable anti-PD-1 antibody pharmaceutical composition and use thereof. The pharmaceutical composition comprises a buffer and an anti-PD-1 antibody or an antigen-binding fragment thereof; wherein the anti-PD-1 antibody or the antigen-binding fragment thereof has a concentration of about 100-250 mg/mL, and comprises an LCDR1, an LCDR2 and an LCDR3 having amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and an HCDR1, an HCDR2 and an HCDR3 having amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and wherein the pharmaceutical composition has a pH of about 5.0-6.5. An injection comprising the pharmaceutical composition and use of the pharmaceutical composition and the injection in preparing a medicament for treating a disease or disorder by eliminating, inhibiting or reducing PD-1 activity.
A stable anti-PD-1 antibody pharmaceutical composition and use thereof. The pharmaceutical composition comprises a buffer and an anti-PD-1 antibody or an antigen-binding fragment thereof; wherein the anti-PD-1 antibody or the antigen-binding fragment thereof has a concentration of about 100-250 mg/mL, and comprises an LCDR1, an LCDR2 and an LCDR3 having amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and an HCDR1, an HCDR2 and an HCDR3 having amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and wherein the pharmaceutical composition has a pH of about 5.0-6.5. An injection comprising the pharmaceutical composition and use of the pharmaceutical composition and the injection in preparing a medicament for treating a disease or disorder by eliminating, inhibiting or reducing PD-1 activity.
The present invention relates to siRNA inhibiting angiogenin-like protein 3 (ANGPTL3) gene expression, an siRNA conjugate and a pharmaceutical composition thereof, and a method of reducing ANGPTL3 gene expression by using the siRNA, and the siRNA conjugate and the pharmaceutical composition thereof. The siRNA, and the siRNA conjugate and the pharmaceutical composition thereof can be used for treating and/or preventing ANGPTL3 gene-mediated diseases or disorders.
The present invention relates to siRNA inhibiting angiogenin-like protein 3 (ANGPTL3) gene expression, an siRNA conjugate and a pharmaceutical composition thereof, and a method of reducing ANGPTL3 gene expression by using the siRNA, and the siRNA conjugate and the pharmaceutical composition thereof. The siRNA, and the siRNA conjugate and the pharmaceutical composition thereof can be used for treating and/or preventing ANGPTL3 gene-mediated diseases or disorders.
Provided are a drug and a method for treating a patient who has undergone complete resection of mucosal melanoma. The present invention particularly relates to the use of an anti-PD-1 antibody or an antigen-binding fragment thereof in the preparation of a drug or a kit for treating a patient who has undergone complete resection of mucosal melanoma or preventing the recurrence or distant metastasis of the mucosal melanoma in the patient. Further provided is a kit for treating a patient who has undergone complete resection of mucosal melanoma or preventing the recurrence or distant metastasis of the mucosal melanoma in the patient. By means of the drug and the method, the RFS of a patient with positive PDL1 expression can be significantly prolonged, and a good tolerance is achieved.
Related to use of an anti-PD-1 antibody in combination with chemotherapy in treating esophageal cancer. In particular, related to use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a chemotherapeutic agent in the preparation of a medicament for treating esophageal cancer. Also related to related drug combination and kit. Related to use of a reagent for detecting a gene amplification of chromosome 11q13 region in a test kit for predicting the therapeutic effect of the anti-PD-1 antibody and/or the antigen-binding fragment thereof on an esophageal cancer patient.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, an expression vector and a host cell for expressing the antibodies or the antigen binding fragments thereof, and therapeutic and diagnostic uses of the antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an anti-PD-L1 single domain antibody and the use thereof. Specifically, provided is an anti-PD-L1 antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region VH, wherein the heavy chain variable region comprises or consists of HCDR1, HCDR2 and HCDR3 respectively having amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; or comprises HCDR1, HCDR2 and HCDR3 having 1, 2 or 3 amino acid differences from the amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively. Further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and a diagnostic method and the pharmaceutical use of the antibody or the antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to a use of an anti-PD-1 antibody in combination with first-line chemotherapy for treating advanced non-small cell lung cancer (NSCLC). In particular, the present invention relates to a use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and a first-line chemotherapeutic drug in the preparation of a drug for treating NSCLC. The present invention also relates to a related pharmaceutical composition and kit.
Provided are an anti-BLyS antibody, a pharmaceutical composition thereof and the use thereof. The anti-BLyS antibody or an antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region; and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the anti-BLyS antibody are respectively as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 are respectively as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The anti-BLyS antibody or the antigen-binding fragment thereof has an excellent binding ability to a human BLyS protein, and the ability to competitively inhibit the binding of human BLyS to a human BR3 receptor thereo. The pharmaceutical composition is a highly stable pharmaceutical composition containing the anti-BLyS antibody and a buffer solution, and may also contain at least one stabilizer and an optional surfactant.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided are a uricase, a pharmaceutical composition thereof and the use thereof. The uricase comprises an amino acid sequence as shown in SEQ ID NO: 9 or a variant thereof. The pharmaceutical composition thereof comprises a buffer solution and a uricase, wherein the pH value of the pharmaceutical composition is about 6.0-8.5, preferably about 7.5-8.1.
The present inventin discloses a method of treating a patient suffering from locally advanced or metastatic urothelial carcinoma, comprising determining a tumor mutational burden of the patient; identifying a candidate exhibiting a high tumor mutational burden, wherein the high tumor mutational burden is ≥ 10 mutations/Mbp; and administering to the candidate a therapeutically effective amount of toripalimab. The present invention also discloses a method of identifying a candidate having mutations in one or more of the following genes occurred in tumor cells: SMARCA4 and RB1.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A SARS-CoV-2 antibody and an application thereof. Provided is an antibody or an antigen-binding fragment thereof that specifically binds to a receptor-binding domain (RBD) of SARS-CoV-2 or a variant thereof. Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen-binding fragment thereof, and a therapeutic and diagnostic method and an application of the antibody or the antigen-binding fragment thereof.
Provided are an IL-21-anti-albumin single-domain antibody fusion protein pharmaceutical composition and use thereof. The pharmaceutical composition comprises an IL-21-anti-albumin single-domain antibody fusion protein and a buffer solution, may further comprise at least one stabilizer, and may optionally further comprise a surfactant. The IL-21-anti-albumin single-domain antibody fusion protein has high stability, and the single drug thereof and the use thereof in combination with the PD-1 monoclonal antibody exert superior anti-tumor activity.
An antibody specifically binding to CD112R or an antigen binding fragment thereof, a composition comprising same, a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen binding fragment thereof, a treatment and diagnostic method using the antibody or the antigen binding fragment thereof, and use of the antibody or the antigen binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
An antibody specifically binding to CD112R or an antigen binding fragment thereof, a composition comprising same, a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a host cell for expressing the antibody or the antigen binding fragment thereof, a treatment and diagnostic method using the antibody or the antigen binding fragment thereof, and use of the antibody or the antigen binding fragment thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition comprises a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof comprises HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to use of an anti-PD-1 antibody in the treatment of a tumor. The present invention also relates to use of a reagent for detecting a gene amplification in the chromosome 11q13 region in a test kit for predicting the therapeutic effect of the anti-PD-1 antibody and/or the antigen-binding fragment thereof on a tumor patient.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided are a bifunctional protein targeting PD-1 or PD-L1 and TGF-β and a medical use thereof. The bifunctional protein comprises: (i) an antigen-binding fragment of an anti-PD-1 or anti-PD-L1 antibody; (ii) an immunoglobulin Fc domain; and (iii) a TGF-β R II extracellular domain (ECD). The bifunctional protein has a stronger affinity with a PD -1 or PD-L1 protein, has good thermal stability, and can significantly promote the release of IFNγ and inhibit the growth of tumors.
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to the use of an anti-PD-1 antibody or an antigen-binding fragment thereof in preparing a drug for preventing or treating a malignant cancer, and the use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and gemcitabine-cisplatin in preparing a drug for preventing or treating a malignant cancer. The malignant cancer is preferably nasopharyngeal carcinoma. The present invention also relates to a method for using a biomarker to predict the therapeutic effect of the anti-PD-1 antibody or the antigen-binding fragment thereof in treatment of nasopharyngeal carcinoma.
Provided are a combination of an anti-PD-1 antibody or an antigen binding fragment of the anti-PD-1 antibody and a cytotoxic anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer. Specifically, Provided are a combination of an anti-PD-1 antibody or an antigen-binding fragment of the anti-PD-1 antibody, an anti-folate metabolism anticancer drug, and a platinum anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer that has failed EGFR-TKI treatment.
The present invention relates to the use of an anti-PD-1 antibody or an antigen-binding fragment thereof in preparing a drug for preventing or treating a malignant cancer, and the use of a combination of an anti-PD-1 antibody or an antigen-binding fragment thereof and gemcitabine-cisplatin in preparing a drug for preventing or treating a malignant cancer. The malignant cancer is preferably nasopharyngeal carcinoma. The present invention also relates to a method for using a biomarker to predict the therapeutic effect of the anti-PD-1 antibody or the antigen-binding fragment thereof in treatment of nasopharyngeal carcinoma.
Provided are a combination of an anti-PD-1 antibody or an antigen binding fragment of the anti-PD-1 antibody and a cytotoxic anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer. Specifically, Provided are a combination of an anti-PD-1 antibody or an antigen-binding fragment of the anti-PD-1 antibody, an anti-folate metabolism anticancer drug, and a platinum anticancer drug, and the use of the combination in the preparation of a medicine for treating non-small cell lung cancer that has failed EGFR-TKI treatment.
An anti-CD3 and anti-CLDN-18.2 bispecific antibody and a use thereof. The anti-CD3 antibody of the present invention contains antigen binding sites that bind to CD3, said CD3 antigen binding sites containing amino acid sequences HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, and amino acid sequences LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21 respectively. The bispecific antibody of the present invention contain antigen binding sites that bind to CD3 and binding sites that bind to CLDN-18.2.
An antibody specifically binding to CTLA-4 or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or an antigen-binding fragment thereof, and therapeutic and diagnostic methods and the use of the antibody or an antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
An antibody specifically binding to CTLA-4 or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or an antigen-binding fragment thereof, and therapeutic and diagnostic methods and the use of the antibody or an antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided are a CLDN-18.2 specific binding antibody or an antigen binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule coding the antibody or the antigen binding fragment thereof, an expression vector and a host cell for expressing the antibody or the antigen binding fragment thereof, and a therapeutic or diagnostic method and use for the antibody or the antigen binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
Provided are a CLDN-18.2 specific binding antibody or an antigen binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule coding the antibody or the antigen binding fragment thereof, an expression vector and a host cell for expressing the antibody or the antigen binding fragment thereof, and a therapeutic or diagnostic method and use for the antibody or the antigen binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention provides a highly concentrated liquid formulation comprising an anti-PCSK9 (human proprotein convertase subtilisin/kexin 9) antibody. The formulation further comprises a buffer, a stabilizer and a surfactant. The liquid formulation disclosed has low viscosity, and the antibody is highly stable after several months of storage.
Provided are a stable pharmaceutical composition of anti-IL-17A antibodies and an application thereof in medicine. The pharmaceutical composition contains anti-IL-17A antibodies or an antigen-binding fragment thereof, and a buffer, can further contain at least one stabilizer, and can optionally further contain a surfactant.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed are a pharmaceutical composition of a humanized monoclonal antibody against novel coronavirus (2019-nCoV) and the use thereof in medicine. The pharmaceutical composition contains an antibody that specifically binds to 2019-nCoV RBD, or an antigen-binding fragment thereof, a buffer, and may also contain at least one stabilizer, and optionally a surfactant.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; medicated candies;
depuratives; medicines for veterinary purposes; fungicides
for agricultural purposes; sanitary tampons; dressings,
medical; teeth filling material; radioactive substances for
medical purposes; biological preparations for medical
purposes.
73.
STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided. (I)
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07C 233/07 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 233/26 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/26 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
C07D 209/28 - 1-(4-Chlorobenzoyl)-2-methyl- indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atomEsters thereof
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided. (I)
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07C 233/07 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 233/26 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/26 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
C07D 209/28 - 1-(4-Chlorobenzoyl)-2-methyl- indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atomEsters thereof
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Disclosed are a pharmaceutical combination of an anti-PD-1 antibody and a multi-receptor tyrosine kinase inhibitor and a method for using same. In particular, the present invention relates to a pharmaceutical combination of an anti-PD-1 antibody and a multi-receptor tyrosine kinase inhibitor, and the use thereof in the preparation of drugs for preventing or treating cancers, and a method for using same.
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
76.
USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORS
Disclosed in the present invention is the use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in treating neuroendocrine tumors. Further disclosed in the present invention are a reagent or kit for detecting ARIDIA gene mutation or amplification, or chromosomal gene rearrangement, and the use of the detection reagent or kit in predicting the curative effect of the anti-PD-1 antibody or the antigen-binding fragment thereof in the treatment of patients with neuroendocrine tumors.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed in the present invention is a use of an anti-PD-1 antibody in treatment of melanoma. Also disclosed is a use of a reagent for detecting BRAF, NRAS, and CDK4/CCND1 gene mutation in a test kit for predicting the treatment effect of individually administering the anti-PD-1 antibody and/or an antigen-binding fragment thereof to patients suffering from melanoma.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an anti-BTLA antibody or an antigen-binding fragment thereof comprising: at least one light chain CDR domain selected from SEQ ID NOs: 7, 8, 9, 10, 11, 12, 16, 17, 18, 22, 23, 24, 31, 32 and 33, and/or at least one heavy chain CDR domain selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 13, 14, 15, 19, 20, 21, 25, 26, 27, 28, 29 and 30. The present invention also relates to a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a corresponding expression vector and a host cell, as well as therapeutic use of the antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the expression vector and the host cell.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention provides a use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in treatment of malignant tumors, particularly in treatment of sarcoma, preferably, a use in treatment of vacuole soft tissue sarcoma, angiosarcoma, and undifferentiated pleomorphic sarcoma, and a use in treatment of lymphoma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
medicines for human purposes for the treatment of cancer, tumor, viral infection, gastrointestinal diseases, the treatment of cardiovascular diseases, intestinal disorders; Medicated candy; Depuratives for the body; Fungicides for agricultural use; sanitary tampons; Medical dressings; teeth filling material; radioactive substances for medical purposes; biological preparations for medical purposes for the treatment of cancer, the prevention of infectious diseases
81.
ANTI-BTLA ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
The present invention provides a stable pharmaceutical composition comprising an anti-BTLA (B and T lymphocyte attenuator) antibody and use thereof in medicines. The pharmaceutical composition comprises an anti-BTLA antibody and a buffer, further comprises at least one stabilizer, and optionally further comprises a surfactant.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
82.
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-BTLA ANTIBODY AND USE THEREOF
Provided are a stable pharmaceutical composition containing an anti-BTLA (B and T lymphocyte attenuator) antibody and the medical use thereof. The pharmaceutical composition contains an anti-BTLA antibody, a buffer solution, at least one stabilizer, and optionally, a surfactant.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The present invention provides a stable pharmaceutical preparation containing an anti-PD-L1 (Programmed death-ligand 1) antibody and a medical application thereof. The preparation contains an anti-PD-L1 antibody and a buffer solution, may further contain at least one stabilizer, and optionally may further contain a surfactant. The pharmaceutical preparation provided by the present invention can effectively inhibit the aggregation of antibodies and prevent the degradation of antibody products, and has high stability.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are improved uricase, a method for treating hyperuricemia using same, and a pharmaceutical composition comprising the uricase. The improved uricase comprises an amino acid sequence having at least about 90% identity to SEQ ID NO: 1, and the sequence is not SEQ ID NO: 1.
Provided are improved uricase, a method for treating hyperuricemia using same, and a pharmaceutical composition comprising the uricase. The improved uricase comprises an amino acid sequence having at least about 90% identity to SEQ ID NO: 1, and the sequence is not SEQ ID NO: 1.
Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, an expression vector and a host cell for expressing the antibodies or the antigen binding fragments thereof, and therapeutic and diagnostic uses of the antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, an expression vector and a host cell for expressing the antibodies or the antigen binding fragments thereof, and therapeutic and diagnostic uses of the antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
medicines for human purposes; Medicated candy; depuratives; medicines for veterinary purposes; Fungicides for agricultural use; sanitary tampons; medical dressings; teeth filling material; radioactive substances for medical purposes; biological preparations for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
medicines for human purposes for the treatment of gastrointestinal diseases, the treatment of cardiovascular diseases, intestinal disorders, alleviating constipation, dental purposes; Medicated candy; Depuratives for the body; medicines for veterinary purposes in the nature of veterinary preparations for pain relief, the treatment of intestinal bacteria, horses, vaccinating cats and dogs; Fungicides for agricultural use; sanitary tampons; Medical dressings; teeth filling material; radioactive substances for medical purposes; biological preparations for medical purposes for the treatment of cancer, the prevention of infectious diseases
There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. (I)
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. (I)
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed are use of an anti-PD-1 antibody in treatment of tumors and use of a reagent for detecting gene amplification of chromosome 11q13 region in preparation of a detection kit for predicting the effect of the PD-1 antibody and/or an antigen binding fragment for treating patients having tumors.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; medicated sweets; depuratives;
medicines for veterinary purposes; germicides for
agriculture; sanitary tampons; dressings, medical; teeth
filling material; radioactive substances for medical
purposes; biological preparations for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; medicated sweets; depuratives;
medicines for veterinary purposes; germicides for
agriculture; sanitary tampons; dressings, medical; teeth
filling material; radioactive substances for medical
purposes; biological preparations for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes, namely, medicinal preparations for headaches; medicated sweets; depuratives for the body; medicines for veterinary purposes, namely, medicinal preparations for intestinal disorders; germicides for agriculture; sanitary tampons; dressings, medical; teeth filling material; radioactive substances for medical purposes; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes, namely, medicinal preparations for headaches; medicated sweets; depuratives for the body; medicines for veterinary purposes, namely, medicinal preparations for intestinal disorders; germicides for agriculture; sanitary tampons; dressings, medical; teeth filling material; radioactive substances for medical purposes; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer
An antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. A nucleic acid molecule encoding said antibody or functional fragment thereof, an expression vector and a host cell for expressing the antibody or the functional fragment thereof, and a method for producing the antibody or the functional fragment thereof. A pharmaceutical composition comprising the antibody or the functional fragment thereof and a method for treating immune dysfunction using the antibody or the functional fragment thereof.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
An antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. A nucleic acid molecule encoding said antibody or functional fragment thereof, an expression vector and a host cell for expressing the antibody or the functional fragment thereof, and a method for producing the antibody or the functional fragment thereof. A pharmaceutical composition comprising the antibody or the functional fragment thereof and a method for treating immune dysfunction using the antibody or the functional fragment thereof.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A liquid formulation containing a high concentration of anti-PCSK9 (human proprotein convertase subtilisin/kexin type 9) antibody. Said formulation further comprises a buffer, a stabilizer and a surfactant. The liquid formulation has a low viscosity, and the antibody has high stability after the formulation has been stored for several months.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
